Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
negativeVykatNegative
AI Analysis
Summary
Neurocrine's approved Prader-Willi syndrome drug Vykat has been linked to seven patient deaths, while Aardvark Therapeutics terminated its Phase 3 trial for the same indication due to cardiac complications, representing significant safety concerns for the therapeutic area.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Seven deaths reported in patients taking Vykat; Aardvark Phase 3 trial terminated due to cardiac complications
Importance:9/10
Sentiment:
-0.95
safety_concerndeathstrial_terminationcardiac_complicationsPrader-Willi syndromeregulatory_risk
Related Companies
Read the original article
Published by BioSpace on August 12, 2026 3:14 PM